GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Annovis Bio ANVS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.90

+6.68%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$28.9m

FY2017FY2025

Free cash flow

−$25.6m

FY2017FY2025

Shareholders' equity

$16.9m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Research and development$25.2m$20.0m$38.8m$16.5m$8.5m$3.1m$776,256$111,608$273,370
Operating income−$29.7m−$26.7m−$45.0m−$25.5m−$14.5m−$6.6m−$1.6m−$713,937−$682,433
Net income−$28.9m−$24.6m−$56.2m−$25.1m−$14.5m−$5.5m−$991,000−$713,871−$682,349
Diluted earnings per share-1.16-1.78-5.90-3.08-1.79-0.79-0.14-0.10-0.02

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$21.1m$13.9m$10.2m$36.0m$46.0m$8.1m$1.1m$50,992$357,963
Cash and short-term investments$19.5m$10.6m$5.8m$28.4m$45.7m$8.1m$1,858$35,312$347,472
Total liabilities$4.2m$4.6m$18.0m$7.7m$1.5m$578,380$9.7m$7.6m$7.3m
Debt——————$499,807——
Shareholders' equity$16.9m$9.3m−$7.8m$28.3m$44.5m$7.5m−$8.6m−$7.6m−$7.0m
Shares outstanding25m14m10m8m8m7m7m7m38m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$25.6m−$21.9m−$40.0m−$17.3m−$9.1m−$4.0m−$476,542−$558,609−$537,481
Capital spending—−$4−$4−$4—−$3———
Free cash flow−$25.6m−$21.9m−$40.0m−$17.3m−$9.1m−$4.0m−$476,542−$558,609−$537,481

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−$14.4m−$18.0m−$9.7m−$7.4m−$6.3m−$6.3m−$6.7m−$4.4m
Net income−$14.8m−$17.6m−$9.8m−$7.3m−$6.2m−$5.5m−$5.9m−$12.6m
Diluted earnings per share-0.40-0.47-0.40-0.29-0.25-0.22-0.43-0.92
Cash from operations−$21.0m−$9.0m−$8.0m−$3.0m−$5.0m−$8.0m−$8.0m−$3.0m
Total assets$22.0m$16.2m$21.1m$17.2m$21.5m$26.7m$13.9m$14.4m
Cash and short-term investments$18.7m$14.2m$19.5m$15.3m$17.1m$22.2m$10.6m$12.6m
Shareholders' equity−$4.3m$3.1m$16.9m$13.2m$18.3m$24.1m$9.3m$7.1m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income5.2%34.9%32.5%
Net income4.7%39.5%19.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-3.0-2.8-1.3-1.8-4.0-1.5

Share price return

Finished calendar years

202520242023202220212020
Return-22%5%-1%-46%715%-34%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.